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Abstract The structure of the cytokine MIF has been
investigated by X-ray crystallography, NMR, and biochemical
methods with conflicting results regarding the structural and
functional oligomerization state of this protein. Determination of
the oligomeric state(s) is important for understanding more
precisely the molecular mechanism of MIF action. To address
this issue, we performed cross-linking of human and mouse MIF
and selected mutants by various methods and analyzed the
oligomerization by SDS-PAGE and gel filtration. MIF was
found to form a mixture of monomeric, dimeric, and trimeric
states at physiological concentrations, with the monomer and
dimer representing the major species. Similar results were
obtained when the carboxy-truncated mutants MIF(1^104) and
MIF(1^109) were examined, indicating that the C-terminus of
MIF is not critical for trimer stabilization. Cross-linking
analysis of the isosteric CysCSer mutants C56S and C80S of
human MIF resulted in a similar oligomer distribution, whereas
substitution of Cys59 led to a significant reduction in the dimeric
and trimeric forms, indicating that the hydrophobic region
around Cys59 is important for the oligomerization of MIF.
Together, our data argue that physiological MIF solutions
contain a mixture of monomers, dimers, and trimers.
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1. Introduction
The biological role of the cytokine macrophage migration
inhibitory factor (MIF) was recently elucidated. MIF is a
pituitary hormone, T cell cytokine, and macrophage-derived
factor with a pro-in£ammatory spectrum of activities [1^4].
MIF was found to be unique in counter-regulating the immu-
no-suppressive and anti-in£ammatory e¡ects of glucocorticoid
hormones [5]. A central regulatory role for MIF within the
host immune and in£ammatory response was demonstrated
when MIF was found to play a role in a number of pathologic
conditions such as septic shock, physiological stress, or certain
immune-mediated diseases [1,5^8]. MIF is exceptional in act-
ing by (additional) enzymatic functions [9^11].
X-ray crystallographic analysis has suggested that MIF is a
trimer of identical subunits that are characterized by an ex-
tended L-sheet and 2 antiparallel K-helices [12^14]. The sub-
units interact to form a symmetrical trimer with the L-sheets
forming a central channel of unknown function. However,
reports about the oligomerization state of MIF have been
contradictory and have varied with the techniques applied.
In addition to the X-ray analyses which suggested that MIF
is a trimer, NMR and biochemical methods have been used.
NMR analysis of human MIF was consistent with the forma-
tion of a MIF dimer [15]. Analytical ultracentrifugation of rat
MIF showed the formation of a dimer [16], while reports
applying gel ¢ltration suggested that MIF is a dimer (human
MIF) [17] or a monomer (bovine MIF) [18]. A study involving
SDS-PAGE of cross-linked mouse MIF indicated that MIF
forms a trimer [19] and is contrast to the other reports that
have investigated the oligomerization state of MIF under sol-
ution conditions. Despite these various reports, no detailed
study of the oligomerization state of MIF has been per-
formed.
The C-terminal sequence stretch of MIF has been suggested
to be important for trimer stabilization [12^14] and thus
would be a good target region for mutational analyses and
investigating the oligomerization state of MIF. We recently
examined the role of the C-terminal residues for the confor-
mation, conformational stability, and biological activity of
MIF [20]. Using two carboxy-truncated mutants of human
MIF with ¢ve and ten residues deleted, we found that the
overall protein structure was not in£uenced by the C-termi-
nus. Although carboxy-truncated MIF showed a somewhat
decreased conformational stability, the enzymatic activity of
the mutants was signi¢cantly retained. However, the mutants
did not show any remaining macrophage-activating e¡ects.
Overall, these data were consistent with the notion that the
trimer may not be the only biologically active form of MIF.
Oligomerization of MIF by covalent disul¢de formation has
essentially been ruled out by electrophoretic and gel ¢ltration
experiments [4], but no mutational analysis has been per-
formed to con¢rm this notion.
To fully characterize the structural and functional oligomer-
ization state of MIF under physiological conditions, we an-
alyzed the size of native MIF by gel ¢ltration and performed
cross-linking of biologically active human MIF (wtMIF) using
di¡erent cross-linking methods. Various solutions containing
physiological and experimental concentrations of MIF were
tested and the cross-linked proteins analyzed by SDS-PAGE
and gel ¢ltration. Cross-linking analysis then was applied to
the carboxy-truncated mutants MIF(1^104) and MIF(1^109)
that lack the putative trimer-stabilizing C-terminal region of
MIF. Moreover, to con¢rm the non-covalent character of any
inter-subunit interactions and to examine the role of the hy-
drophobic region around Cys59, various cysteine mutants of
human MIF were subjected to the cross-linking analysis.
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2. Materials and methods
2.1. Materials
Miscellaneous chemicals and enzymes were bought from Sigma-Al-
drich Chemicals (Deisenhofen, Germany) and were of the highest
grade commercially available. All molecular biology reagents includ-
ing primers for polymerase chain reaction-based cloning of wtMIF
and the mutants were acquired from Gibco BRL (Eggenstein, Ger-
many) or New England Biolabs GmbH (Heidelberg, Germany). Bis-
[L-(4-azidosalicylamindo)ethyl]disul¢de (BASED) was obtained from
Pierce (Rockford, IL).
2.2. Site-directed mutagenesis, cloning, bacterial expression, and
puri¢cation of wtMIF and the mutants
Human MIF was ampli¢ed originally from Jurkat H33HJ-JA1
T cell DNA and cloned into the pET11b expression vector [4]. The
C-terminal deletion mutants and the isosteric CysCSer mutants of
human MIF were cloned from huMIF/pET11b by DNA ampli¢cation
as described elsewhere ([20], Kleemann et al., manuscript submitted).
Bacterial expression and puri¢cation of wtMIF and the mutants is
described in detail elsewhere ([4], Kleemann et al., manuscript sub-
mitted, [20]). Brie£y, wtMIF, the carboxy-truncated mutants, and the
CysCSer mutants (except for mutant C59S) were expressed and pu-
ri¢ed essentially following the established protocol for wtMIF [4],
using isopropyl-1-thio-L-D-galactopyranoside-induced overexpression
of proteins in pET11b/E. coli BL21(DE3) and puri¢cation of recombi-
nant protein by the anion exchange and C8-SepPak reverse-phase
two-step chromatography procedure, and renaturation of acetoni-
trile-denatured protein by controlled dialysis. Puri¢cation of mutant
C59S was performed by a separate method involving extraction of the
protein from inclusion bodies, gel ¢ltration, and C8 reverse-phase
chromatography (described in detail elsewhere; Kleemann et al.,
manuscript submitted).
2.3. Protein cross-linking
Biological activity of the renatured recombinant proteins was con-
¢rmed prior to the cross-linking experiments using an enzyme or
macrophage-activating bioassay [20].
Cross-linking with glutaraldehyde: Wild-type or mutant MIF pro-
tein at the indicated concentrations was dissolved in 20 mM sodium
phosphate bu¡er (pH 7.2) and incubated for 3 h in the presence of 1%
glutaraldehyde [21]. The reaction was stopped by adding NaBH4 (2 M
in 0.1 M NaOH) to a ¢nal concentration of 50 mM and the cross-
linked products stabilized. After 20 min, sodium deoxycholate was
added (¢nal concentration of 0.01%) and the pH of the mixture low-
ered to 2.0 with an aqueous 78% trichloroacetic acid (TCA) solution.
After centrifugation (20 min, 13 000Ug, 4‡C), products were neutral-
ized with ammonium hydroxide, boiled in Laemmli sample bu¡er, and
analyzed by SDS-PAGE under reducing conditions. For examining
concentration dependency of oligomer formation, cross-linking was
performed between a concentration range of 0.1 WM and 18 WM
MIF protein. Additional lower (6 0.1 WM) and higher (s 20 WM)
concentrations of MIF were not investigated due to experimental
di⁄culties pertaining to the handling of large volumes at low protein
concentrations and insolubility of the renatured MIF, respectively.
Cross-linking e⁄ciency and electrophoretic behavior of cross-linked
oligomers was controlled by using the trimeric cytokine tumor ne-
crosis factor-K (concentration: 1 WM). By this standard, a s 95%
cross-linking e⁄ciency was achieved.
Cross-linking with Bis-[L-(4-azidosalicylamindo)ethyl]disul¢de
(BASED): BASED was dissolved in DMSO and added to the MIF-
containing solution (¢nal BASED concentration: 0.6 mg/ml). Photo-
activation was performed by exposing the sample to long wave UV
light (366 nm; room temperature) for 30 min at a distance of 3 cm.
Cross-linked samples were TCA-precipitated as described above and
electrophoresed under non-reducing conditions.
2.4. Gel ¢ltration HPLC
Native size exclusion chromatography was performed on a Toso-
haas TSK G2000SWXL HPLC column (300U7.8 mm, Tosohaas,
Stuttgart, Germany) at a £ow rate of 0.25 ml/min using a 50 mM
sodium phosphate bu¡er (pH 7.2). For denaturing gel ¢ltration, a 50
mM sodium phosphate bu¡er (pH 7.2) containing 7 M guanidine
hydrochloride (GdnHCl) was used.
2.5. SDS-PAGE
For SDS-PAGE, cross-linked proteins were electrophoresed in 20%
homogenous polyacrylamide gels using the Pharmacia PhastGel elec-
trophoresis system (Pharmacia, Upsala, Sweden). The gels were silver-
stained according to the manufacturer’s protocol, scanned, and the
relative quantities of the monomeric and oligomeric forms estimated
by densitometry analysis with the program ScionImageNT (Scion
Corp., Frederick, MD). It should be noted that in normal SDS-
PAGE analyses of MIF, a faint non-covalent dimer band is frequently
observed and is likely to result from non-covalent hydrophobic inter-
actions between subunits.
3. Results and discussion
To begin to characterize the oligomerization state(s) of
MIF, biologically active MIF was subjected to gel ¢ltration
chromatography under non-denaturing conditions. Con¢rm-
ing previous reports using native methods for size determina-
tion [16,17], we found that native recombinant human or
mouse MIF chromatographed as a dimer (apparent molecular
mass = 27 000 Da; data not shown). By contrast, acetonitrile-
denatured MIF eluted at a volume that corresponded to the
monomeric species (apparent molecular mass = 13 000 Da). Of
note, analysis of the renatured recombinant proteins is likely
to fully represent the behavior of the natural eukaryotic MIF
as MIF is not secreted by endoplasmatic reticulum-mediated
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Fig. 1. SDS-PAGE and silver staining of wtMIF after cross-linking. A: Comparison of wild-type human (huMIF) and mouse MIF (muMIF)
with TNF-K. Cross-linking was performed with glutaraldehyde at a protein concentration of 1 WM. Control reactions without cross-linker were
analyzed for comparison. B: Dependence of oligomerization on the protein concentration during cross-linking with glutaraldehyde. Wild-type
MIF at the indicated concentrations was cross-linked. C: Cross-linking with the photo-cross-linker BASED. Wild-type human MIF at a con-
centration of 1 WM was cross-linked with BASED and electrophoresed. Molecular weight markers (Mr) are indicated. +, sample cross-linked
prior to electrophoresis; 3, non-cross-linked control.
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pathways and thus is not glycosylated. The latter modi¢cation
is known otherwise to interfere with protein-protein interac-
tions and association of monomers. Moreover, it is widely
established that the recombinant MIF protein exhibits full
natural-like biological activity [1^5,20]. In native gel ¢ltration,
interference of the supporting matrix with subunit interactions
is not excluded. Therefore, we used a principle covalent cross-
linking approach in conjunction with denaturing conditions to
circumvent this potential problem. First, biologically active
wtMIF was dissolved at physiological concentrations and
the protein subjected to chemical cross-linking by glutaralde-
hyde. MIF was used at a concentration of 1 WM in 20 mM
sodium phosphate bu¡er (pH 7.2). Fig. 1A is a SDS-PAGE of
cross-linked human wtMIF in comparison to the non-cross-
linked protein. Cross-linked wtMIF was found to consist of a
mixture of monomeric, dimeric, and trimeric forms, whereas
only monomeric MIF was detected when MIF was electro-
phoresed without prior cross-linking. Analysis of mouse MIF
resulted in an identical oligomer distribution. Estimation of
the relative densities of the protein bands of human MIF
showed that 44% migrated as monomer and 33% of the pro-
tein formed dimers, whereas only 23% trimers were seen.
Under the conditions used, MIF exhibits full cytokine and
enzymatic activity [2,4,20]. Of note, baseline serum concentra-
tions of MIF readily rise into the low micromolar range upon
immune stimulation of experimental animals and similar con-
centrations have been measured in the synovium of mice that
were manipulated to develop rheumatoid arthritis [22], sug-
gesting together that the applied low micromolar concentra-
tions, although unusual for a cytokine, represent physiological
conditions.
The observed detection of MIF monomers may represent
correctly the physiological oligomer distribution, but may also
be due to incomplete cross-linking. Thus to better control for
a maximal cross-linking e⁄ciency, the cytokine TNF-K which
has a similar molecular mass as MIF and which is known to
form non-covalently linked homo-trimers in solution [23], was
treated under the same conditions and used as a control. As
expected, cross-linked TNF-K was found to form s 95%
trimers and non-cross-linked TNF-K migrated as a monomer
(Fig. 1A). It would thus appear that detection of monomeric
MIF in the cross-linked reactions represents a true association
state.
One factor that in£uences subunit association of oligomeric
proteins is the protein concentration and frequently, structural
studies are not performed at physiological concentrations. In
particular, X-ray crystallography and NMR require much
higher protein concentrations (about 1 mM) than those phys-
iologically found for MIF, i.e. in the low and submicromolar
range [2,4,20]. To address this potential problem, we per-
formed cross-linking of MIF over a broad range of protein
concentrations spanning both physiological concentrations
(0.1 to 1 WM) and higher experimental concentrations (1 to
18 WM). Renatured recombinant MIF exhibiting biological
activity is not soluble above a concentration of 20^25 WM
and therefore, no higher concentrations were tried to avoid
non-speci¢c subunit interaction. No concentration-dependent
di¡erences were observed over the concentration range tested
when cross-linking of these preparations was performed with
1% glutaraldehyde and all reactions were found to contain an
identical oligomer distribution (Fig. 1B). This indicated that
MIF exists in the same assembly state within the tested con-
centration range. As additional lower and higher MIF con-
centrations could not be tested in this experiment due to ex-
perimental di⁄culties (see Section 2.3), we cannot rule out
that concentration-dependent e¡ects would be observed at
these concentrations. In fact, one would expect that further
dilution of the MIF solution may result in the ultimate dis-
sociation of oligomers into the monomeric species.
One criticism that is often leveled upon chemical cross-link-
ing analyses using glutaraldehyde is the occurrence of artefac-
tual protein subunit linkage due to glutaraldehyde auto-
polymerization. The above examination of the concentration
dependency of the cross-linking of MIF already indicated that
the observed oligomer distribution pattern was speci¢c. More-
over, occurrence of a mixture of monomeric, dimeric, and
trimeric forms in physiological MIF solutions was con¢rmed
using another cross-linking agent, BASED. Cross-linking with
BASED and the subsequent electrophoretic analysis resulted
in a similar distribution of oligomers as seen in the glutaral-
dehyde cross-linking reactions, with 59% monomer, 29%
dimer, and 12% trimer (Fig. 1C). Cross-linking yields with
photo-reactive reagents such as BASED have been found to
be low for many proteins [24]. Thus, it was not unexpected
that the oligomer distribution was shifted somewhat towards
the monomer in the BASED cross-linking experiment. Despite
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Fig. 3. SDS-PAGE and silver staining of the carboxy-truncated and
CysCSer mutants of MIF after cross-linking with glutaraldehyde.
Mutant proteins at a concentration of 1 WM were cross-linked with
glutaraldehyde and samples electrophoresed as indicated. Wild-type
MIF and non-cross-linked samples were analyzed for comparison.
Molecular weight markers (Mr) are indicated. +, sample cross-linked
prior to electrophoresis; 3, non-cross-linked control.
Fig. 2. Gel ¢ltration HPLC analysis of cross-linked wild-type hu-
man MIF. The column was calibrated with standard proteins as de-
scribed in Section 2. After cross-linking with glutaraldehyde, MIF
was chromatographed under denaturing conditions. The elution vol-
umes of the marker proteins (1, bovine serum albumin; 2, carbonic
anhydrase; 3, cytochrom c; 4, aprotinin) are indicated. a, peak
eluted at ca. 12 400 Da; b, peak eluted at ca. 27 000 Da.
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this disadvantage, cross-linking with BASED represented an
important control, because unlike most protein cross-linking
agents, the BASED reaction does not rely upon the amino
side chains of lysine and arginine. Cross-linking by BASED
is based upon non-speci¢c photo-activation and thus, is not
restricted by amino side chain distances and steric hindrances.
In fact, we were unable to achieve any cross-linking of MIF
with the prominent cross-linking agent disuccinimidyl suber-
ate (DSS) (data not shown). Inspection of the inter-amino side
chain distances of lysine and arginine residues in both mono-
meric MIF and the dimeric and trimeric forms showed that
the spacer length of this chemical was considerably smaller
than the distances between the amino groups (Fig. 4).
Gel ¢ltration analysis under denaturing conditions, i.e. in
the presence of 7 M guanidine hydrochloride, of cross-linked
MIF was then used to con¢rm the molecular masses and
relative portions of the MIF oligomers. Fig. 2 shows the elu-
tion pro¢le of a 25 Wg MIF sample that was cross-linked with
1% glutaraldehyde at a protein concentration of 1 WM prior to
chromatography. Two protein fractions were detected and
found to have apparent molecular masses of 27 000 and
12 400, thus corresponding to dimeric and monomeric MIF,
respectively. Of note, signi¢cant portions of trimeric MIF
were not detected by the gel ¢ltration analysis. The failure
of the denaturing gel ¢ltration analysis to detect trimers while
this species was readily seen in the SDS-PAGE method is not
obvious. However, it may be speculated that the trimeric spe-
cies tends to aggregate more easily than dimeric or monomeric
MIF and that aggregates would then be lost by non-speci¢c
binding to the resin. Although unusual, such a behavior has
been reported for amyloidogenic proteins/peptides and may
also occur under denaturing chromatography conditions
[25,26].
Together, electrophoretic and gel ¢ltration analysis of the
various cross-linked wtMIF preparations suggested that phys-
iological MIF solutions consist of a mixture of monomeric,
dimeric, and trimeric association states. Surprisingly, the
trimer, which was determined by X-ray crystallography to
be the predominant (or only) species, was found to represent
only a minor portion in physiological MIF solutions.
The carboxy-terminal region of MIF has been implicated in
the stabilization of trimer formation [13,14]. To examine the
contribution of the C-terminal region for oligomer formation
and to further investigate the physiological occurrence of MIF
trimers, we applied the described glutaraldehyde cross-linking
procedure to the C-terminal deletion mutants MIF(1^104)
and MIF(1^109). Overall, oligomerization of MIF was found
to be altered only slightly by the deletion of either the ¢ve or
ten C-terminal residues (Fig. 3). However, a more detailed
analysis by densitometric scanning showed that MIF(1^109)
and MIF(1^104) formed 33% and 32% dimers, and 27% and
29% trimers, respectively, with the remainder consisting of
monomers. Thus, contrary to the predicted trimer-stabilizing
e¡ect of the C-terminal region, trimer formation was found to
be elevated in the mutant preparations. The observed failure
of both deletion mutants to activate macrophages in the
Leishmania killing assay [20] may therefore not be due to
reduced trimer formation of these mutants. Consequently,
the prior conclusion that the immunological e¡ects of MIF
were mediated by MIF trimers and that the trimer may be the
receptor-active species may not be correct. Based on data
measured by X-ray crystallography, it had been suggested
that two or three C-terminal L-strands were important for
the stabilization of the MIF trimer [12,14]. We previously
found that deletion of the C-terminus led to a decrease in
the conformational stability of MIF [20], an observation
that was consistent with the trimer-stabilizing role of the C-
terminus. However, the present results would indicate that
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Fig. 4. Three-dimensional structure of human MIF. A: Ribbon
structure of the MIF monomer. Hydrophobic residues on the L-
sheet side are marked. The hydrophobic character of the residues
was determined following to the scale of Wolfenden et al. [43]. The
positions of the cysteines are indicated by the notations C56, C59,
and C80. B: Proposed model of the MIF dimer. Figures were pre-
pared using the program MOLSCRIPT [44].
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conformational stabilization of MIF is not critically depend-
ent on the formation of trimers.
Cross-linking of the isosteric cysteine mutants C56S and
C80S resulted in the same oligomer distribution as that seen
for wtMIF (26 and 29% dimer, and 18 and 24% trimer, re-
spectively) (Fig. 3). This ¢nding con¢rmed earlier data which
had indicated that subunit association of MIF is not mediated
by covalent, intermolecular disul¢de bridging [4,11]. More-
over, these data are consistent with recent ¢ndings that the
measured disul¢des of MIF [11,27] represent intramolecular
disul¢de bonding and that these disul¢des are of functional
rather than structural character [11]. By contrast, mutant
C59S behaved di¡erently and was found to form a signi¢-
cantly decreased portion of trimers (27% dimer and 10%
trimer). X-ray crystallography of MIF shows that both cys-
teines of the Cys56-Ala-Leu-Cys59 motif are located in a highly
hydrophobic environment. Cys59 is closely surrounded by Ile4,
Leu58, Tyr95 and Ile96 with additional hydrophobic residues in
near proximity [14] (Fig. 4A). Substitution of Cys59 by Ser is
likely to lower the hydrophobicity of this region, thus provid-
ing a smaller area for hydrophobic interactions. Interestingly,
disturbance of the hydrophobic character of this region by
modi¢cation of Cys59 ([28], R. Kleemann, unpublished obser-
vations) has been proposed to be responsible for a local con-
formational change together with a signi¢cant change in the
biological activity of MIF.
Our results provide evidence that MIF forms a mixture of
monomers, dimers, and trimers in physiological solutions,
with the monomer and the dimer representing the predomi-
nant species. The trimer is only a minor species. This ¢nding
was con¢rmed by our mutational analysis of the C-terminal
region of MIF. This region had been suggested by the X-ray
crystallographic analyses to stabilize trimer formation, but
cross-linking analysis of our C-terminal deletion mutants
showed increased rather than decreased trimer formation.
Thus, the present data are not consistent with the X-ray crys-
tallographic results. X-ray crystallography is surely the most
prominent method for determining protein structures. How-
ever, although no simple packing due to mass action of sub-
units was observed [14] with this method for MIF, one may
argue that the high protein concentrations used in crystallog-
raphy, i.e. approximately 1 mM, do not represent physiolog-
ical concentrations. At high protein concentrations, a given
equilibrium mixture of di¡erent oligomeric states could then
be shifted towards the larger association state, resulting in
crystallization of this form. Dependence of the association
state of oligomeric cytokines on protein concentration has
been shown for the proteins interleukin-8 (IL-8), monocyte
chemoattractant protein (MCP-1), I-309, and neutrophil-acti-
vating peptide 2 [29^31]. Also, IL-8 has been shown to form
di¡erent oligomeric states at physiological concentrations ver-
sus the crystallographic or NMR conditions. Under physio-
logical solution conditions, IL-8 is monomeric and this form
is biologically active [29,32^34]. In contrast, the available crys-
tal and NMR structures of IL-8 show that this protein is a
dimer [35,36]. Incidentally, the MIF monomer is somewhat
reminiscent of the IL-8 dimer [14]. MCP-1 was shown to
form both monomeric and dimeric crystals and it has not
been resolved ¢nally whether it functions as a monomer or
dimer in solution [29,30,37,38]. For other cytokines, it has
been shown that their oligomeric state in solution and in the
crystal are identical. For example, TNF-K and interferon-Q
form a trimer and dimer, respectively [39^41], regardless of
the method applied. Furthermore, the oligomeric state relates
directly to the mode of activation of the receptor of these
cytokines. The TNF-K trimer was found to induce receptor
trimerization and the interferon-Q dimer leads to receptor di-
merization [39,42]. To date, no receptor has been identi¢ed for
MIF.
We suggest that in solution MIF oligomer formation may
be determined by the protein concentration or by signaling
events such as receptor activation or substrate binding that
may favor one oligomeric state. Our data indicate that the
favored oligomer might well be the dimer or the monomer.
A possible arrangement of subunits in the dimer is depicted in
Fig. 4B. In this model, several hydrophobic residues located in
the four-stranded L-sheet of each subunit plus in the inter-
connecting loops, together forming a hydrophobic area (Fig.
4A), would provide for inter-subunit interactions within the
dimer (Fig. 4B).
However, from the data it may not be fully excluded that
putative receptor activation by MIF occurs from the minor
trimeric state. Further mutational analyses evaluating the con-
tact sites between subunits in the dimer and trimer are in
progress and should assist in obtaining the speci¢c oligomers
in soluble form to selectively measure their biological activ-
ities.
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